About Us
Science Driven.
Therapeutically Focused.
Unparalleled Metabolic Experience.
About Us

Connecting clients, partners and patients to advance clinical research and the development of breakthrough treatments for metabolic disease.

our focus

our services

ProSciento's portfolio of global services, exclusively focused on metabolic diseases, provides flexible solutions that meet the specific needs of clients from large pharma to virtual and small biotechnology companies.

Our Values

ProSciento is proud to be driven by strong values. We take tremendous pride in the impact our team has made in science, for patients and in our community.

Read More »

Executives
Leadership.
Integrity.
Making a Difference.

15+
globally
commercialized
drugs & devices

ProSciento’s executive leadership is internationally recognized for their contributions to the field of metabolic drug development, including program strategy, clinical trial conduct, regulatory submissions, and post-marketing research across all phases of the product development cycle.

Marcus Hompesch

Marcus Hompesch, M.D.

Chief Executive Officer and Chairman of the Board

Dr. Marcus Hompesch is Chief Executive Officer and Chairman of the Board at ProSciento. His career in clinical research and involvement in mechanistic clinical studies for diabetes, insulin resistance and metabolism spans more than 25 years both in academic and industry settings. At ProSciento he has led the company since its inception in the U.S. in 2003 and has overseen its growth from a a diabetes-focused clinical research facility to a metabolism-focused, full scope clinical R&D service provider.

Prior to leading ProSciento, Dr. Hompesch was Chief Operating Officer of Profil Institute for Metabolic Research, GmbH and before that was founder and Chief Executive Officer of the medical technology company Med.IQ. He is also a scientific advisor to many life science companies.

Read More »
Linda Morrow

Linda Morrow, M.D.

Vice President and Chief Operating Officer

Dr. Linda Morrow is Chief Operating Officer at ProSciento. Her career in clinical research and experimental studies for insulin resistance, diabetes mellitus, and carbohydrate metabolism spans more than 20 years. She leads the clinical operations team for the US’s only early phase metabolic focused CRO and oversees a state-of-the-art clinical research facility. Her team develops and applies advanced metabolic methodologies, resulting in an industry wide reputation as the leading team for early phase diabetes research and one of only a few CROs with an expertise in conducting NAFLD/NASH first-in-human studies. Dr. Morrow has acted as principal investigator for more than 80 clinical research studies for metabolic small and large molecule therapies, biologics, biosimilars, and devices. Prior to her focus in clinical research, Dr. Morrow was a practicing physician, as well as holding faculty member positions at the University of Michigan and Harvard’s Division on Aging.

Read More »
Markus Hoffman

Markus Hofmann

Chief Financial Officer

Markus Hofmann is ProSciento’s Chief Financial Officer overseeing the company’s accounting and financial operations. Mr. Hofmann has had a leadership role in ProSciento’s finance department since 2013 when he joined the company as Corporate Controller and Vice President of Financial Services. Prior to this, Mr. Hofmann was an executive level financial consultant for ProSciento and Volcano Corporation, a public medical device company, specializing in streamlining accounting processes; identifying key metrics to track a company’s financial performance; and systemizing stock and similar administration plans. Before his role as a consultant, Mr. Hofmann was the Controller at Verari Systems, Inc., a private technology company, and Genetronics, Inc., a public medical device company. Mr. Hofmann has a Bachelor’s degree in Business from Coleman College and is a Certified Public Accountant (CPA), Certified Management Accountant (CMA), and Certified in Financial Management (CFM).

Board of Directors
Building scientific knowledge.
Driving innovation.
Achieving success.

ProSciento's Board members have been at the forefront of metabolic research and drug development, both in industry and academia, and have held leadership positions at more than 25 life science companies.

Marcus Hompesch, M.D.

Chief Executive Officer and Chairman of the Board

Kelvin Logan, Ph.D.

Industry consultant and former President of Europe, Asia and Latin America at INC Research

John Amatruda, M.D.

Pharmaceutical Research Executive and Former Senior Vice President and Head of Diabetes and Obesity at Merck Research Laboratories

Linda Morrow, M.D.

Vice President and Chief Operating Officer

Dan Bradbury

Managing Member of BioBrit, LLC and former Amylin Pharmaceutical CEO

Jerrold Olefsky, M.D.

Professor of Medicine at the University of California, San Diego (UCSD) Division of Endocrinology and Metabolism and the Associate Dean of Scientific Affairs for the UCSD School of Medicine